PCT1 / Pan Cancer T - LARVOL DELTA

Pan Cancer T Secures EUR 10 Million to Advance First-in-Human Trial of Novel TCR-T Cell Therapy for Triple-Negative Breast Cancer (GlobeNewswire) - "The financing includes EUR 5 million from existing investors Van Herk Ventures, Thuja Capital, Erasmus MC O&O Holdings, and InnovationQuarter, in addition to a EUR 5 million Innovation Credit loan from the Dutch Ministry of Economic Affairs. This funding will enable the company to treat TNBC patients at leading cancer centres in the Netherlands....'This significant investment marks a pivotal moment..., following our planned regulatory filing with the EMA in 2026'....The upcoming trial will assess safety, tolerability, and preliminary efficacy of a therapeutic dose of PCT1:CO-STIM in TNBC patients."

Financing • First-in-human • New trial • Triple Negative Breast Cancer

PCT1:CO-STIM TCR T-cells to target triple-negative breast cancer and overcome its hostile tumor micro-environment (CICON 2025) - "Notably, PCT1:CO-STIM showed no crossreactivity, no alloreactivity nor tonic signaling. Conclusion We identified ROPN1 as promising target for adoptive T-cell therapy for TNBC, selected a specific and active TCR, further enhanced it with CO-STIM engineering and put forward PCT1:CO-STIM TCR for clinical testing."

Biomarker • IO biomarker • Tumor microenvironment • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CD8 • ICOS • TRB

PCT1:CO-STIM TCR T-cells to overcome the hostile tumor micro-environment and target triple-negative breast cancer. (ASCO 2025) - "TCR:CO-STIM technology has shown enhanced activity of a selective and specific TCR targeted at ROPN1 and we are progressing PCT1:CO-STIM to the clinic for the treatment of TNBC."

Biomarker • IO biomarker • Tumor microenvironment • Breast Cancer • Melanoma • Oncology • Solid Tumor • Triple Negative Breast Cancer

PCT1:co-stim TCR T-cells to target triple-negative breast cancer and overcome its hostile micro-environment (SITC 2024) - "In vivo regression of TNBC following single treatment with T-cells or repeated dosing of Sacituzumab-govitecan. C. Real-time imaging of GFP+TNBC cells upon repeated co-culture with T-cells"

IO biomarker • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CD8 • HAVCR2 • LAG3 • PD-1

PCT1:co-stim TCR T-cells to target triple-negative breast cancer and overcome its hostile micro-environment (SITC 2024) - "In vivo regression of TNBC following single treatment with T-cells or repeated dosing of Sacituzumab-govitecan. C. Real-time imaging of GFP+TNBC cells upon repeated co-culture with T-cells"

IO biomarker • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CD8 • HAVCR2 • LAG3 • PD-1